What is the recommended dose of enoxaparin (low molecular weight heparin) in patients with acute coronary syndrome (ACS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Enoxaparin Dosing in Acute Coronary Syndrome

The recommended dose of enoxaparin in acute coronary syndrome (ACS) is 1 mg/kg subcutaneously every 12 hours, with dose reduction to 1 mg/kg once daily for patients with creatinine clearance <30 mL/min. 1

Initial Therapy Dosing

  • For standard initial therapy in ACS: 1 mg/kg subcutaneously every 12 hours 1
  • For patients with renal impairment (CrCl <30 mL/min): Reduce dose to 1 mg/kg subcutaneously once daily 1
  • An initial intravenous loading dose of 30 mg has been used in selected patients, though this is not mandatory for all patients 1

Dosing When Supporting PCI

For patients who have received prior enoxaparin treatment and are proceeding to PCI:

  • If last subcutaneous dose was administered 8-12 hours earlier or only 1 subcutaneous dose has been given: Administer IV dose of 0.3 mg/kg 1
  • If last dose was administered within previous 8 hours: No additional enoxaparin needed 1
  • For patients who have not received prior anticoagulant therapy: 0.5-0.75 mg/kg IV bolus 1

Dosing With Fibrinolytic Therapy

  • For patients <75 years: 30 mg IV bolus, followed in 15 minutes by 1 mg/kg subcutaneously every 12 hours (maximum 100 mg for first 2 doses) 1
  • For patients ≥75 years: No bolus, 0.75 mg/kg subcutaneously every 12 hours (maximum 75 mg for first 2 doses) 1
  • Regardless of age, if CrCl <30 mL/min: 1 mg/kg subcutaneously every 24 hours 1

Special Considerations and Cautions

  • Accurate weight-based dosing is critical - studies show that approximately 19% of patients receive excess doses (>10 mg above recommended), which significantly increases bleeding risk (43% higher odds of major bleeding) 2
  • Elderly patients, those with low body weight, and females are at higher risk of receiving excess doses 2
  • Concomitant use of enoxaparin with antiplatelet agents (particularly clopidogrel) increases bleeding risk, especially in older patients 3
  • For patients who may require open heart surgery while on enoxaparin, there is an increased risk of re-exploration for postoperative bleeding compared to unfractionated heparin 4

Duration of Therapy

  • Enoxaparin should be continued for the duration of hospitalization or until PCI is performed 1
  • Premature discontinuation of anticoagulation is associated with a rebound increase in thrombin activity and risk of reinfarction, with greatest risk in the first 4-8 hours after discontinuation 1

Careful attention to proper dosing based on weight and renal function is essential to optimize outcomes while minimizing bleeding complications in patients with ACS receiving enoxaparin 5, 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.